Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Core Insights - Incannex Healthcare Inc. is advancing its PSX-001 program for generalized anxiety disorder by forming a Clinical Advisory Board (CAB) to provide clinical and regulatory guidance [1][2] Group 1: Clinical Advisory Board Formation - The newly established CAB consists of leading experts in psychiatry, neurobiology, and psychopharmacology, aimed at enhancing the scientific rigor and patient-focused approach of the PSX-001 development strategy [2] - The CAB will advise on clinical trial design, endpoint selection, regulatory engagement, and broader strategic approaches as the PSX-001 program progresses [2] Group 2: Expert Profiles - Dr. C. Neill Epperson, an expert in psychiatry and women's brain health, has over 30 years of NIH-funded research experience and has authored more than 220 peer-reviewed publications [4] - Dr. Charles B. Nemeroff, a recognized authority in mood and anxiety disorders, has published over 1,300 scientific articles and leads multiple research initiatives in neuroscience and psychiatric medicine [5] - Dr. Alan F. Schatzberg, a pioneer in depressive disorders, has more than 700 publications and has held leadership roles in major psychiatric associations [6] Group 3: Company Overview - Incannex Healthcare is focused on developing combination medicines targeting chronic conditions, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [7] - The company is advancing three clinical-stage product candidates, with PSX-001 being an oral synthetic psilocybin treatment for generalized anxiety disorder [8]